160586-68-5

Usage

Uses

Used in Organic Synthesis:
4-(Toluene-4-sulfonyloxymethyl)-piperidine-1-carboxylic acid benzyl ester, 98% is used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique functional groups and reactivity allow for the formation of diverse chemical structures, making it a versatile component in the synthesis of specialty chemicals and materials.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-(Toluene-4-sulfonyloxymethyl)-piperidine-1-carboxylic acid benzyl ester, 98% is used as a key intermediate in the synthesis of bioactive molecules and pharmaceutical drugs. Its structural features and chemical properties enable the development of novel drug candidates with potential therapeutic applications.
Used in Medicinal Chemistry:
4-(Toluene-4-sulfonyloxymethyl)-piperidine-1-carboxylic acid benzyl ester, 98% is utilized in medicinal chemistry for the design and optimization of drug molecules. Its unique functional groups and reactivity contribute to the generation of new chemical entities with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Drug Development:
In the drug development process, 4-(Toluene-4-sulfonyloxymethyl)-piperidine-1-carboxylic acid benzyl ester, 98% serves as a valuable precursor for the synthesis of potential drug candidates. Its incorporation into drug molecules can lead to the discovery of new therapeutic agents with novel mechanisms of action and improved safety profiles.
Overall, 4-(Toluene-4-sulfonyloxymethyl)-piperidine-1-carboxylic acid benzyl ester, 98% is a versatile and valuable chemical compound with a wide range of applications in organic synthesis, pharmaceutical research, medicinal chemistry, and drug development. Its unique structural features and reactivity make it an essential building block for the creation of innovative and effective chemical and pharmaceutical products.

Upstream product

• 501-53-1 benzyl chloroformate 
• 6457-49-4 4-piperidinemethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 122860-33-7 benzyl 4-(hydroxymethyl)piperidine-N-carboxylate 

Downstream Products

• 652130-42-2 1-benzyloxycarbonyl-4-[(5,6-dimethoxy-2-ethoxycarbonylindan-1-on-2-yl)methyl]piperidine 
• 676125-69-2 4-(6-fluoro-indol-1-ylmethyl)-piperidine-1-carboxylic acid benzyl ester 
• 1613464-93-9 (S)-benzyl 4-((3-(((tert-butoxycarbonyl)amino)(phenyl)methyl)phenoxy)methyl)piperidine-1-carboxylate 
• 259143-04-9 4-piperidinemethylfluoride 

Relevant academic research and scientific papers

Design and Synthesis of Novel N-(2-aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study

Histone deacetylases (HDACs) are promising therapeutic targets for cancer therapy because inhibition of HDACs triggers growth arrest or apoptosis of tumor cells. In the present study, a new series of fluorinated N-(2-aminophenyl)benzamide derivatives were synthesized to investigate potential inhibition of HDACs and associated anticancer activity. Among the synthesized derivatives, compound 24a showed potent inhibitory activity of HDACs and higher antitumor efficacy in human cancer cell lines (HCT-116, MCF-7, and A549) compared with SAHA. Moreover, animal studies demonstrated that compound 24a showed potent in vivo antitumor efficacy in an HCT-116 colon cancer xenograft mouse model.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

4-Methylsulfonyl-Substituted Piperidine Urea Compounds

The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

Discovery of orally available integrin α5β1 antagonists

Previous research within our laboratories identified the 3-hydroxypyrrolidine scaffold 1 as a new and selective integrin α5β1 inhibitor class which was designed for local administration. Herein the discovery of new orally available integrin α5β1 inhibitor scaffolds for potential systemic treatment is described.